mesalamine and Diverticulitis studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Research Excerpts

Excerpt	Relevance	Reference
"We evaluated the efficacy and safety of multimatrix mesalamine vs placebo in the prevention of recurrent diverticulitis in 590 (PREVENT1) and 592 (PREVENT2) adult patients with ≥1 episodes of acute diverticulitis in the previous 24 months that resolved without surgery."	9.19	Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. ( Barrett, K; Jamal, MM; Kamm, MA; Márquez, J; Melzer, E; Raskin, JB; Schoen, RE; Streck, P; Szalóki, T, 2014)
"We evaluated the efficacy of mesalamine (Asacol) in reducing gastrointestinal symptoms after an acute attack of diverticulitis."	9.17	A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. ( Magowan, S; Quigley, EM; Shanahan, F; Stollman, N, 2013)
"To evaluate the impact of mesalamine administration on inflammatory response in acute uncomplicated diverticulitis."	7.81	Effect of oral mesalamine on inflammatory response in acute uncomplicated diverticulitis. ( Bernasconi, DP; Gianotti, L; Lo Bianco, G; Nespoli, A; Nespoli, L; Romano, F; Uggeri, F, 2015)
"We evaluated the efficacy and safety of multimatrix mesalamine vs placebo in the prevention of recurrent diverticulitis in 590 (PREVENT1) and 592 (PREVENT2) adult patients with ≥1 episodes of acute diverticulitis in the previous 24 months that resolved without surgery."	5.19	Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. ( Barrett, K; Jamal, MM; Kamm, MA; Márquez, J; Melzer, E; Raskin, JB; Schoen, RE; Streck, P; Szalóki, T, 2014)
"We evaluated the efficacy of mesalamine (Asacol) in reducing gastrointestinal symptoms after an acute attack of diverticulitis."	5.17	A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. ( Magowan, S; Quigley, EM; Shanahan, F; Stollman, N, 2013)
"To evaluate the impact of mesalamine administration on inflammatory response in acute uncomplicated diverticulitis."	3.81	Effect of oral mesalamine on inflammatory response in acute uncomplicated diverticulitis. ( Bernasconi, DP; Gianotti, L; Lo Bianco, G; Nespoli, A; Nespoli, L; Romano, F; Uggeri, F, 2015)
"In SAG-37, the proportion of recurrence-free patients during 48 weeks was 67."	2.84	Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. ( Banai, J; Björck, S; Bunganic, I; Curtin, A; Derova, J; Diez Alonso, MM; Dilger, K; Dorofeyev, AE; Eisenbach, T; Ferreira, N; Greinwald, R; Kardalinos, V; Kondrackiene, J; Kruis, W; Lukas, M; Mäkelä, J; Mohrbacher, R; Pokrotnieks, J; Safadi, R; Spiller, R; Talley, NJ; Tuculanu, D; Tulassay, Z; Vich, T; Zakko, SF, 2017)
"Recurrence of diverticulitis is frequent within 5 years from the uncomplicated first attack, and its prophylaxis is still unclear."	2.78	Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration. ( Bargiggia, S; Bortoli, A; Casella, G; De Pretis, G; Ferrari, A; Germanà, B; Giacosa, A; Miori, G; Parente, F; Prada, A, 2013)
"Diverticulitis is the most severe form of Diverticular disease (DD)."	2.66	Is mesalazine treatment effective in the prevention of diverticulitis? A review. ( Ashktorab, H; Frieri, G; Latella, G; Stefanelli, G; Valvano, M; Vernia, F; Viscido, A, 2020)
"The incidence of diverticulosis and diverticular disease of the colon is increasing worldwide."	2.61	Diverticulosis today. ( Brandimarte, G; Elisei, W; Tursi, A, 2019)
"Diverticulitis is therefore increasingly treated using conservative or drug therapy."	2.55	[Diverticulitis : Domain of conservative or drug therapy?] ( Böhm, S; Kruis, W, 2017)
"Conservative measures in prevention recurrence are dietary advises and medical therapies, including probiotics and 5-aminosalicylic acid."	2.48	Systematic review of medical therapy to prevent recurrent diverticulitis. ( Boermeester, MA; Daniels, L; Unlü, C; Vrouenraets, BC, 2012)

Research

Studies (35)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Change in GSS From Baseline to Week 12 - ITT Population

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (11.43)	29.6817
2010's	29 (82.86)	24.3611
2020's	2 (5.71)	2.80

Authors	Studies
Balk, EM	1
Adam, GP	1
Cao, W	1
Mehta, S	1
Shah, N	1
Stefanelli, G	1
Viscido, A	1
Valvano, M	1
Vernia, F	1
Frieri, G	1
Ashktorab, H	1
Latella, G	1
Festa, V	1
Spila Alegiani, S	1
Chiesara, F	1
Moretti, A	1
Bianchi, M	1
Dezi, A	1
Traversa, G	1
Koch, M	1
Kruis, W	3
Kardalinos, V	1
Eisenbach, T	1
Lukas, M	1
Vich, T	1
Bunganic, I	1
Pokrotnieks, J	1
Derova, J	1
Kondrackiene, J	1
Safadi, R	1
Tuculanu, D	1
Tulassay, Z	1
Banai, J	1
Curtin, A	1
Dorofeyev, AE	1
Zakko, SF	1
Ferreira, N	1
Björck, S	1
Diez Alonso, MM	1
Mäkelä, J	1
Talley, NJ	1
Dilger, K	1
Greinwald, R	2
Mohrbacher, R	1
Spiller, R	1
Böhm, S	1
Urushidani, S	1
Kuriyama, A	1
Matsumura, M	1
Gracie, DJ	1
Ford, AC	1
Elisei, W	1
Brandimarte, G	2
Tursi, A	6
Iannone, A	1
Ruospo, M	1
Wong, G	1
Barone, M	1
Principi, M	1
Di Leo, A	1
Strippoli, GFM	1
Carabotti, M	1
Annibale, B	1
Stollman, N	3
Magowan, S	1
Shanahan, F	1
Quigley, EM	1
Parente, F	1
Bargiggia, S	1
Prada, A	1
Bortoli, A	1
Giacosa, A	1
Germanà, B	1
Ferrari, A	1
Casella, G	1
De Pretis, G	1
Miori, G	1
Raskin, JB	2
Kamm, MA	2
Jamal, MM	1
Márquez, J	1
Melzer, E	1
Schoen, RE	1
Szalóki, T	1
Barrett, K	1
Streck, P	3
Danese, S	1
Floch, MH	1
Jaung, R	1
Robertson, J	1
Vather, R	1
Rowbotham, D	1
Bissett, IP	1
Nespoli, L	1
Lo Bianco, G	1
Uggeri, F	1
Romano, F	1
Nespoli, A	1
Bernasconi, DP	1
Gianotti, L	1
Strate, LL	2
Peery, AF	2
Neumann, I	1
Smalley, W	1
Hirano, I	1
Humes, D	2
Spiller, RC	2
Dai, C	2
Jiang, M	2
Sun, MJ	2
Festi, D	1
Colecchia, A	1
Simpson, J	1
Hall, J	1
Hammerich, K	1
Roberts, P	1
Joseph, RE	1
Unlü, C	1
Daniels, L	1
Vrouenraets, BC	1
Boermeester, MA	1
Modi, R	1
Cohen, E	1
Spiegel, BM	1
Rinas, U	1
Adamek, HE	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis[NCT00695643]	Phase 3	345 participants (Actual)	Interventional	2008-01-31	Terminated
Double-blind, Dose-response, Randomised, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis[NCT01038739]	Phase 3	330 participants (Actual)	Interventional	2010-01-31	Terminated (stopped due to Stopped due to futility.)
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of a 12 Week Treatment of Acute Diverticulitis With Asacol® 2.4 g/Day (400 mg Mesalamine Tablet), Followed by a 9 Month Treatment-free Observation Period[NCT00554099]	Phase 2	117 participants (Actual)	Interventional	2007-11-30	Completed
[NCT01120340]	Phase 3	105 participants (Actual)	Interventional	2005-10-31	Completed
A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.[NCT00545740]	Phase 3	590 participants (Actual)	Interventional	2007-11-28	Completed
A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.[NCT00545103]	Phase 3	592 participants (Actual)	Interventional	2007-12-06	Completed
Clinical Trial for the Determination of Advanced Colonic Neoplasia Prevalence and the Need for Colonoscopy in Complicated and Uncomplicated Acute Diverticulitis[NCT03557216]		313 participants (Actual)	Interventional	2018-06-15	Completed
Randomized Multicentric Controlled Clinical Trial of Parallel Groups to Evaluate the Non-therapeutic Inferiority of a Free Diet With a Progressive Diet, in the Treatment of Non-complicated Acute Diverticulitis[NCT03496090]		134 participants (Actual)	Interventional	2018-04-16	Completed
[NCT02003807]		102 participants (Actual)	Observational	2013-07-31	Completed
Multicentre Controlled, Randomized Clinical Trial to Compare the Efficacy and Safety of Ambulatory Treatment of Mild Acute Diverticulitis Without Antibiotics With the Standard Treatment With Antibiotics[NCT02785549]	Phase 4	480 participants (Actual)	Interventional	2016-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: Baseline to Week 12

Change in GSS From Baseline to Week 52 - ITT Population

Intervention	Scores on a Scale (Mean)
Placebo	-16.14
Mesalamine	-17.63
Mesalamine & Probiotic	-16.11

Global Symptom Score (GSS) at Week 12, Primary Efficacy Population

Intervention	Scores on a Scale (Mean)
Placebo	-16.82
Mesalamine	-17.30
Mesalamine & Probiotic	-16.00

Percentage of Responders at Week 12 - ITT Population

Intervention	Scores on a Scale (Mean)
Placebo	7.3
Mesalamine	4.4
Mesalamine & Probiotic	5.9

Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: 12 Weeks

Percentage of Responders at Week 52 - ITT Population

Intervention	Percentage of Participants (Number)
Placebo	41.4
Mesalamine	62.5
Mesalamine & Probiotic	48.1

Recurrent Diverticulitis, Percentage, ITT Population, Week 12

Intervention	Percentage of Participants (Number)
Placebo	50.0
Mesalamine	66.7
Mesalamine & Probiotic	29.2

At least one report of recurrent diverticulitis since the last visit (prior to the Week 12 visit). (NCT00554099)
Timeframe: 12 Weeks

Recurrent Diverticulitis, Percentage, ITT Population, Week 52

Intervention	Percentage of Participants (Number)
Placebo	20.0
Mesalamine	12.5
Mesalamine & Probiotic	11.8

At least one report of recurrent diverticulitis since the last visit (prior to the Week 52 visit). (NCT00554099)
Timeframe: 52 Weeks

Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12

Percent of Subjects Requiring Surgery for Diverticulitis

Percent of Subjects Who Were CT-Recurrence Free of Diverticulitis

Intervention	Percentage of Participants (Number)
Placebo	31.0
Mesalamine	28.1
Mesalamine & Probiotic	37.0

Intervention	Percentage of Participants (Number)
Placebo	2.4
Mesalamine	5.0
Mesalamine & Probiotic	0.0

Intervention	percentage of subjects (Number)
SPD476 (1.2 g)	2.8
SPD476 (2.4 g)	2.8
SPD476 (4.8 g)	3.3
Placebo	2.0

CT-recurrence of diverticulitis is defined as: a positive spiral CT scan for diverticulitis showing, at a minimum, fat stranding with or without bowel wall thickening >5 mm or surgical intervention for diverticular disease. Withdrawals considered as CT-recurrences. (NCT00545740)
Timeframe: Up to 104 weeks

Percent of Subjects Without Recurrence of Diverticulitis

Intervention	percentage of subjects (Number)
SPD476 (1.2 g)	61.5
SPD476 (2.4 g)	62.2
SPD476 (4.8 g)	52.7
Placebo	63.9

Recurrence of diverticulitis is defined as the presence of each and all of the following 3 items: 1) abdominal pain, 2) a 15% increase in white blood cell count from baseline, 3) bowel wall thickening (>5 mm) and/or fat stranding as evidenced by spiral computerized axial tomography (CT) scan; OR surgical intervention for diverticular disease. Withdrawals are considered as recurrences. (NCT00545740)
Timeframe: Up to 104 weeks

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Negative

Intervention	percentage of subjects (Number)
SPD476 (1.2 g)	62.2
SPD476 (2.4 g)	62.9
SPD476 (4.8 g)	52.7
Placebo	64.6

A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Positive

Intervention	Number of CT scans (Number)
	Negative	Presence of abdominal pain	15% increase in WBC from baseline	Presence of abdominal pain + 15% increase in WBC
Placebo	3	3	1	1
SPD476 (1.2 g)	0	0	0	0
SPD476 (2.4 g)	3	2	1	0
SPD476 (4.8 g)	2	2	0	0

A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Negative

Intervention	Number of CT scans (Number)
	Positive	Presence of abdominal pain	15% increase in WBC from baseline	Presence of abdominal pain + 15% increase in WBC
Placebo	1	1	0	0
SPD476 (1.2 g)	0	0	0	0
SPD476 (2.4 g)	0	0	0	0
SPD476 (4.8 g)	1	1	0	0

A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Positive

Intervention	Number of CT scans (Number)
	Negative	Presence of abdominal pain	15% increase in WBC from baseline	Presence in abdominal pain + 15% increase in WBC
Placebo	10	7	1	1
SPD476 (1.2 g)	19	19	5	5
SPD476 (2.4 g)	10	8	2	2
SPD476 (4.8 g)	5	5	2	2

A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545740)
Timeframe: Up to 104 weeks

Percent of Subjects Requiring Surgery for Diverticulitis

Percent of Subjects Who Are CT-Recurrence Free of Diverticulitis

Intervention	Number of CT scans (Number)
	Positive	Presence of abdominal pain	15% increase in WBC from baseline	Presence in abdominal pain + 15% increase in WBC
Placebo	38	37	24	23
SPD476 (1.2 g)	37	30	17	17
SPD476 (2.4 g)	39	39	24	24
SPD476 (4.8 g)	55	54	28	28

Intervention	percentage of subjects (Number)
SPD476 (1.2 g)	4.7
SPD476 (2.4 g)	2.7
SPD476 (4.8 g)	2.0
Placebo	1.4

Percent of Subjects Without Recurrence of Diverticulitis

Intervention	percentage of subjects (Number)
SPD476 (1.2 g)	62.8
SPD476 (2.4 g)	59.2
SPD476 (4.8 g)	69.1
Placebo	66.9

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Negative

Intervention	percentage of subjects (Number)
SPD476 (1.2 g)	62.8
SPD476 (2.4 g)	59.2
SPD476 (4.8 g)	69.1
Placebo	67.6

A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 weeks

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Positive

Intervention	Number of CT Scans (Number)
	Negative	Presence of abdominal pain	15% increase in WBC from baseline	Abdominal pain + 15% increase in WBC
Placebo	0	0	0	0
SPD476 (1.2 g)	1	1	0	0
SPD476 (2.4 g)	0	0	0	0
SPD476 (4.8 g)	0	0	0	0

A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 weeks

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Negative

Intervention	Number of CT Scans (Number)
	Positive	Presence of abdominal pain	15% increase in WBC from baseline	Abdominal pain + 15% increase in WBC
Placebo	1	1	0	0
SPD476 (1.2 g)	0	0	0	0
SPD476 (2.4 g)	0	0	0	0
SPD476 (4.8 g)	1	0	0	0

A negative CT scan was defined as a CT scan that did not show bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 weeks

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Positive

Intervention	Number of CT Scans (Number)
	Negative	Presence of abdominal pain	15% increase in WBC from Baseline	Abdominal pain + 15% increase in WBC
Placebo	15	12	4	3
SPD476 (1.2 g)	9	8	1	1
SPD476 (2.4 g)	8	6	2	2
SPD476 (4.8 g)	22	17	4	4

A positive CT scan was defined as a CT scan that showed bowel wall thickening (>5 mm) and/or fat stranding as read by the central reader. (NCT00545103)
Timeframe: up to 104 Weeks

Article	Year
Evaluation and Management After Acute Left-Sided Colonic Diverticulitis : A Systematic Review. Annals of internal medicine, 2022, Volume: 175, Issue:3 Topics: Colonoscopy; Diverticulitis; Diverticulitis, Colonic; Humans; Mesalamine; United States	2022
Is mesalazine treatment effective in the prevention of diverticulitis? A review. European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:15 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Humans; Mesalamine; Probiotics; Rifaximin	2020
[Diverticulitis : Domain of conservative or drug therapy?] Der Internist, 2017, Volume: 58, Issue:7 Topics: Anti-Bacterial Agents; Conservative Treatment; Diverticulitis; Humans; Mesalamine; Probiotics; Rando	2017
5-aminosalicylic acid agents for prevention of recurrent diverticulitis: A systematic review and meta-analysis. Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Anti-Inflammatory Agents; Database	2018
Diverticulosis today. Minerva gastroenterologica e dietologica, 2019, Volume: 65, Issue:1 Topics: Acute Disease; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Dietary Fiber; Divert	2019
Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials. Canadian journal of gastroenterology & hepatology, 2018, Volume: 2018 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticular Diseases; Diverticulitis; Diverticulum, Colon;	2018
Mesalamine (5-ASA) for the prevention of recurrent diverticulitis (Review). Techniques in coloproctology, 2019, Volume: 23, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Humans; Mesalamine; Recurrence; Secondary P	2019
Changes in the approach to acute diverticulitis. ANZ journal of surgery, 2015, Volume: 85, Issue:10 Topics: Acute Disease; Anti-Bacterial Agents; Anti-Inflammatory Agents; Diverticulitis; Diverticulitis, Colo	2015
Colonic diverticular disease: medical treatments for acute diverticulitis. BMJ clinical evidence, 2016, Feb-04, Volume: 2016 Topics: Acute Disease; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Human	2016
Colonic diverticular disease. BMJ clinical evidence, 2007, Aug-15, Volume: 2007 Topics: Acute Disease; Diverticulitis; Diverticulitis, Colonic; Diverticulosis, Colonic; Diverticulum; Human	2007
New paradigms in the management of diverticular disease. Current problems in surgery, 2010, Volume: 47, Issue:9 Topics: Age Factors; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Diagnosis, D	2010
Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Digestive diseases and sciences, 2011, Volume: 56, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Gastrointestinal Agents; Humans; Mesalamine	2011
Systematic review of medical therapy to prevent recurrent diverticulitis. International journal of colorectal disease, 2012, Volume: 27, Issue:9 Topics: Anti-Bacterial Agents; Dietary Fiber; Diverticulitis; Humans; Mesalamine; Probiotics; Recurrence	2012
Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. The American journal of gastroenterology, 2012, Volume: 107, Issue:10 Topics: Abdominal Pain; Acute Disease; Age Distribution; Anti-Infective Agents; Anti-Inflammatory Agents, No	2012
Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. The American journal of gastroenterology, 2012, Volume: 107, Issue:10 Topics: Abdominal Pain; Acute Disease; Age Distribution; Anti-Infective Agents; Anti-Inflammatory Agents, No	2012
Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. The American journal of gastroenterology, 2012, Volume: 107, Issue:10 Topics: Abdominal Pain; Acute Disease; Age Distribution; Anti-Infective Agents; Anti-Inflammatory Agents, No	2012
Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. The American journal of gastroenterology, 2012, Volume: 107, Issue:10 Topics: Abdominal Pain; Acute Disease; Age Distribution; Anti-Infective Agents; Anti-Inflammatory Agents, No	2012
[Diverticulosis/diverticulitis? What are conservative therapy possibilities?]. Medizinische Klinik (Munich, Germany : 1983), 2006, Jan-15, Volume: 101, Issue:1 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-	2006

Article	Year
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Double-Blind Method; Female; Humans; Male;	2017
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Double-Blind Method; Female; Humans; Male;	2017
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Double-Blind Method; Female; Humans; Male;	2017
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Double-Blind Method; Female; Humans; Male;	2017
A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of clinical gastroenterology, 2013, Volume: 47, Issue:7 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Bifidobacter	2013
Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration. International journal of colorectal disease, 2013, Volume: 28, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Confidence Intervals; Demography; Diverticulitis; Double-Blind Metho	2013
Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology, 2014, Volume: 147, Issue:4 Topics: Adult; Aged; Anti-Inflammatory Agents; Colectomy; Colonic Diseases; Diverticulitis; Female; Gastroin	2014
Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology, 2014, Volume: 147, Issue:4 Topics: Adult; Aged; Anti-Inflammatory Agents; Colectomy; Colonic Diseases; Diverticulitis; Female; Gastroin	2014
Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology, 2014, Volume: 147, Issue:4 Topics: Adult; Aged; Anti-Inflammatory Agents; Colectomy; Colonic Diseases; Diverticulitis; Female; Gastroin	2014
Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology, 2014, Volume: 147, Issue:4 Topics: Adult; Aged; Anti-Inflammatory Agents; Colectomy; Colonic Diseases; Diverticulitis; Female; Gastroin	2014

Article	Year
Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis. European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Diverticulitis; Female; Humans; Male; Mesalamine; Middle Aged; Recur	2017
Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin. Authors' reply. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:4 Topics: Diverticulitis; Diverticulitis, Colonic; Humans; Mesalamine	2017
Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin. Authors' reply. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:4 Topics: Diverticulitis; Diverticulitis, Colonic; Humans; Mesalamine	2017
Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin. Authors' reply. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:4 Topics: Diverticulitis; Diverticulitis, Colonic; Humans; Mesalamine	2017
Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin. Authors' reply. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:4 Topics: Diverticulitis; Diverticulitis, Colonic; Humans; Mesalamine	2017
Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:4 Topics: Diverticulitis; Diverticulitis, Colonic; Humans; Mesalamine	2017
Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:4 Topics: Diverticulitis; Diverticulitis, Colonic; Humans; Mesalamine	2017
Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:4 Topics: Diverticulitis; Diverticulitis, Colonic; Humans; Mesalamine	2017
Editorial: mesalazine to prevent recurrent acute diverticulitis-the final nail in the coffin. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:4 Topics: Diverticulitis; Diverticulitis, Colonic; Humans; Mesalamine	2017
Preventing diverticulitis recurrence by selecting the right therapy for a complex disease. Gastroenterology, 2014, Volume: 147, Issue:4 Topics: Anti-Inflammatory Agents; Colonic Diseases; Diverticulitis; Female; Gastrointestinal Agents; Humans;	2014
Preventing diverticulitis: mesalamine may still be indicated in the decision. Gastroenterology, 2015, Volume: 148, Issue:4 Topics: Anti-Inflammatory Agents; Colonic Diseases; Diverticulitis; Female; Gastrointestinal Agents; Humans;	2015
Reply: To PMID 25167986. Gastroenterology, 2015, Volume: 148, Issue:4 Topics: Anti-Inflammatory Agents; Colonic Diseases; Diverticulitis; Female; Gastrointestinal Agents; Humans;	2015
Effect of oral mesalamine on inflammatory response in acute uncomplicated diverticulitis. World journal of gastroenterology, 2015, Jul-21, Volume: 21, Issue:27 Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bioma	2015
American Gastroenterological Association Institute Technical Review on the Management of Acute Diverticulitis. Gastroenterology, 2015, Volume: 149, Issue:7 Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Diet; Diverticulitis; Gas	2015
American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis. Gastroenterology, 2015, Volume: 149, Issue:7 Topics: Acute Disease; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colonoscop	2015
American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis. Gastroenterology, 2015, Volume: 149, Issue:7 Topics: Acute Disease; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colonoscop	2015
American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis. Gastroenterology, 2015, Volume: 149, Issue:7 Topics: Acute Disease; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colonoscop	2015
American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis. Gastroenterology, 2015, Volume: 149, Issue:7 Topics: Acute Disease; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colonoscop	2015
Antibiotics for Acute Uncomplicated Diverticulitis: Time for a Paradigm Change? Gastroenterology, 2015, Volume: 149, Issue:7 Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Diet; Diverticulitis; Gas	2015
Mesalamine in Recurrent Acute Colonic Diverticulitis. The American journal of gastroenterology, 2016, Volume: 111, Issue:11 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Diverticulitis, Colonic; Hum	2016
"Mesalazine in the Treatment of Symptomatic Uncomplicated Diverticular Disease: Reply". Journal of clinical gastroenterology, 2019, Volume: 53, Issue:3 Topics: Colon; Diverticular Diseases; Diverticulitis; Humans; Mesalamine; Primary Prevention; Randomized Con	2019
Mesalazine in the Treatment of Symptomatic Uncomplicated Diverticular Disease. Journal of clinical gastroenterology, 2019, Volume: 53, Issue:1 Topics: Colon; Diverticular Diseases; Diverticulitis; Humans; Mesalamine; Primary Prevention; Randomized Con	2019
Mesalazine and rifaximin in symptomatic uncomplicated diverticular disease. The American journal of gastroenterology, 2009, Volume: 104, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Diverticulum, Colon; Gastrointestinal Agent	2009
Diverticular disease: what is the best long-term treatment? Nature reviews. Gastroenterology & hepatology, 2010, Volume: 7, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Gastrointestinal Agents; Humans; Mesalamine	2010
Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Medical science monitor : international medical journal of experimental and clinical research, 2004, Volume: 10, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Drug Therap	2004

mesalamine and Diverticulitis

Research Excerpts

Research

Studies (35)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Change in GSS From Baseline to Week 12 - ITT Population

Change in GSS From Baseline to Week 52 - ITT Population

Global Symptom Score (GSS) at Week 12, Primary Efficacy Population

Percentage of Responders at Week 12 - ITT Population

Percentage of Responders at Week 52 - ITT Population

Recurrent Diverticulitis, Percentage, ITT Population, Week 12

Recurrent Diverticulitis, Percentage, ITT Population, Week 52

Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12

Percent of Subjects Requiring Surgery for Diverticulitis

Percent of Subjects Who Were CT-Recurrence Free of Diverticulitis

Percent of Subjects Without Recurrence of Diverticulitis

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Negative

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Positive

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Negative

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Positive

Percent of Subjects Requiring Surgery for Diverticulitis

Percent of Subjects Who Are CT-Recurrence Free of Diverticulitis

Percent of Subjects Without Recurrence of Diverticulitis

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Negative

Number of CT Scans Performed More Than 7 Days From Suspected Recurrence of Diverticulitis That Were Positive

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Negative

Number of CT Scans Performed Within 7 Days of Suspected Recurrence of Diverticulitis That Were Positive

Reviews

Trials

Other Studies